Bitter taste receptors inside cancer cells have been found to be activated in the presence of anti-cancer drugs. Shutting ...
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
The Brighterside of News on MSN
Scientists create special antibody that shuts down rogue T cells safely
A promising breakthrough in autoimmune disease research may open the door to safer and more effective treatments. Scientists ...
Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...
The first patient has been dosed in a Phase 1 trial testing the experimental CAR T-cell therapy obecabtagene autoleucel for progressive MS.
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted ...
A new artificial intelligence (AI) tool can simultaneously assess blood samples for infections, autoimmune diseases, and vaccine responses, according to a new study. The algorithm analyzed genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback